Further analyses of mechanisms underlying the antinociceptive effect of the triterpene 3β, 6β, 16β-trihydroxylup-20(29)-ene in mice.

The present study investigated the mechanisms involved in the antinociception produced by the triterpene 3β, 6β, 16β-trihydroxylup-20(29)-ene (TTHL) in mice. TTHL administered by intra-gastric (i.g.) gavage inhibited glutamate-induced nociception with an ID(50) of 19.0 (13.2-27.5) mg/kg. This action started 60 min (inhibition of: 59±6%) after i.g. administration and remained significant up to 6h (inhibition of 37±6%). Moreover, TTHL inhibited both phases of formalin induced pain. The antinociception of TTHL was reversed by the pre-administration of naloxone (1mg/kg; non-selective opioid receptor antagonist), CTOP (1mg/kg; selective μ-opioid receptor antagonist), nor-binaltorphimine (1mg/kg; selective κ-opioid receptor antagonist), naltrindol (3mg/kg; selective δ-opioid receptor antagonist), p-chlorophenylalanine methyl ester (100mg/kg for 4 consecutive days; inhibitor of serotonin synthesis), WAY100635 (0.5mg/kg; selective 5-HT(1A) receptor antagonist) and ketanserin (0.3mg/kg; selective 5-HT(2A) receptor antagonist) but not by L-arginine (600 mg/kg; nitric oxide precursor) or ondansetron (0.5mg/kg; 5-HT(3) receptor antagonist). Furthermore, the TTHL antinociception was prevented by intrathecal (i.t.) pre-treatment with pertussis toxin (0.5 μg/site; inactivator of G(i/o) protein), charybdotoxin (250 pg/site; blocker of large-conductance calcium-gated K(+) channels), tetraethylammonium (1 μg/site; blocker of voltage-gated K(+) channels) and glibenclamide (80 μg/site; blocker of ATP-gated K(+) channels) but not by apamin (50 ng/site; blocker of small-conductance calcium-gated K(+) channels). The antinociception of TTHL was not it associated with locomotor impairment or sedation. These results showed that TTHL presented a pronounced antinociceptive effect, which is dependent on opioid and serotonergic systems, G(i/o) protein activation and the opening of specific K(+) channels.